Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea Green Light For Pfizer’s Novel Breast Cancer Drug

Executive Summary

Pfizer's first-in-class breast cancer drug Ibrance is set to debut in South Korea following a regulatory approval and will offer a new option for the growing number of patients in the country.

You may also be interested in...

ASCO Puts A Spotlight On CDK4/6 Category Ahead Of New Competition

Data to be presented at ASCO in June suggests Pfizer’s Ibrance has a good shot at maintaining a leadership position in the category as competitors Lilly and Novartis step closer to the market.

Among New Drug Launches, Oncology Scores Big While CV Lags

Bristol’s Opdivo and Pfizer’s Ibrance are standouts among recent drug launches, well on their way to becoming commercial blockbusters, while new cardiovascular drugs like Repatha, Praluent and Entresto, forecast to become blockbusters in their own right, have been slow at launch, restrained by market access.

Asia Deal Watch: Busy Eikon Partners With Impact On Selective PARP1 Inhibitors

Yuhan and J INTS BIO and Betta and C4 sign deals centered on lung cancer candidates. Viatris’s Japanese affiliate gets in-country rights to InDex’s Phase III ulcerative colitis candidate.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts